Sanofi (NASDAQ:SNY) Sees Unusually-High Trading Volume

Sanofi (NASDAQ:SNY) saw strong trading volume on Tuesday . 4,504,486 shares changed hands during trading, an increase of 126% from the previous session’s volume of 1,989,371 shares.The stock last traded at $48.37 and had previously closed at $48.86.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Sanofi Stock Performance

The company has a market capitalization of $120.24 billion, a price-to-earnings ratio of 23.88, a price-to-earnings-growth ratio of 1.52 and a beta of 0.60. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The company’s fifty day simple moving average is $48.34 and its two-hundred day simple moving average is $48.47.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, April 25th. The company reported $0.96 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.96. Sanofi had a net margin of 10.52% and a return on equity of 26.25%. The company had revenue of $11.36 billion for the quarter, compared to the consensus estimate of $11.75 billion. Equities research analysts predict that Sanofi will post 4.11 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Thursday, June 6th. Investors of record on Friday, May 10th were given a $1.478 dividend. The ex-dividend date of this dividend was Thursday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.38. This represents a yield of 2.98%. Sanofi’s dividend payout ratio (DPR) is currently 74.37%.

Institutional Trading of Sanofi

Several hedge funds have recently bought and sold shares of the company. Rise Advisors LLC increased its stake in Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after buying an additional 251 shares during the period. Salem Investment Counselors Inc. acquired a new position in shares of Sanofi in the 4th quarter worth approximately $27,000. Venturi Wealth Management LLC grew its stake in shares of Sanofi by 163.5% in the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after purchasing an additional 332 shares during the last quarter. Frazier Financial Advisors LLC acquired a new position in shares of Sanofi in the 4th quarter worth approximately $28,000. Finally, Larson Financial Group LLC grew its stake in shares of Sanofi by 480.8% in the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after purchasing an additional 500 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.